Published in N Engl J Med on January 31, 1974
Controlled study of atenolol in treatment of hypertension. Br Med J (1975) 1.41
Metabolic and cardiovascular side effects of the beta 2-adrenoceptor agonists salbutamol and rimiterol. Br J Clin Pharmacol (1980) 1.30
Comparison of the effects on renin release of beta adrenergic antagonists with differing properties. J Clin Invest (1974) 1.05
The effects of beta-adrenoceptor blockade on renin, angiotensin, aldosterone and catecholamines at rest and during exercise. Br J Clin Pharmacol (1979) 0.93
Evidence for the participation of beta1-adrenoceptors in isoprenaline-induced renin release from rat kidny slices in vitro. Br J Pharmacol (1978) 0.84
The effect of pindolol on plasma renin activity and blood pressure in hypertensive patients. Br J Clin Pharmacol (1976) 0.80
Antihypertensive action of beta-adrenoceptor blockade and the renin-angiotensin system. Br J Clin Pharmacol (1979) 0.78
Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet (1985) 8.35
Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet (1998) 6.20
Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet (1999) 3.81
Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med (1999) 3.43
Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol (2005) 3.34
Renal effects of cadmium body burden of the general population. Lancet (1990) 2.90
Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly. Lancet (1978) 2.56
Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet (1986) 2.50
Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med (1997) 2.40
Impairment of renal function with increasing blood lead concentrations in the general population. The Cadmibel Study Group. N Engl J Med (1992) 2.17
Renal function, cytogenetic measurements, and sexual development in adolescents in relation to environmental pollutants: a feasibility study of biomarkers. Lancet (2001) 2.13
Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med (1994) 2.12
Reference values for self-recorded blood pressure: a meta-analysis of summary data. Arch Intern Med (1998) 2.01
Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization. Aging (Milano) (1991) 1.93
Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens (2003) 1.93
Nocturnal blood pressure fall on ambulatory monitoring in a large international database. The "Ad Hoc' Working Group. Hypertension (1997) 1.90
Hemodynamic response to graded exercise after chronic beta-adrenergic blockade. J Appl Physiol Respir Environ Exerc Physiol (1977) 1.85
Comparative potency of atenolol and propranolol as beta-adrenergic blocking agents in man. Eur J Clin Pharmacol (1976) 1.80
Bradycardia, ventricular pauses, syncope, and sports. Lancet (1984) 1.77
A new method to determine frequency characteristics of the respiratory system. J Appl Physiol (1976) 1.76
Thrombolytic therapy with streptokinase using a standard dosage scheme. Br Med J (1966) 1.75
The protein tyrosine kinase p56lck inhibits CD4 endocytosis by preventing entry of CD4 into coated pits. J Cell Biol (1992) 1.67
Anthropometry, carbohydrate and lipid metabolism in the East Flanders Prospective Twin Survey: heritabilities. Diabetologia (2007) 1.56
Beta-blockers: once or three times a day? Br Med J (1978) 1.54
Isolated systolic hypertension in the elderly. J Hypertens (1990) 1.48
Renal function and historical environmental cadmium pollution from zinc smelters. Lancet (1994) 1.45
Human immunodeficiency virus gp120 and derived peptides activate protein tyrosine kinase p56lck in human CD4 T lymphocytes. Eur J Immunol (1993) 1.42
[Hemodynamic effects of urapidil in men]. Presse Med (1990) 1.41
Salt intake and blood pressure in the general population: a controlled intervention trial in two towns. J Hypertens (1988) 1.39
Captopril and agranulocytosis. Lancet (1980) 1.36
Blood pressure and urinary cations in urban Bantu of Zaire. Am J Epidemiol (1986) 1.30
Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J Hypertens (2001) 1.30
Noninvasive assessment of seasonal variations in cardiac structure and function in cyclists. Circulation (1983) 1.29
The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens (1997) 1.27
Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol (1981) 1.26
Exposure to cadmium and conventional and ambulatory blood pressures in a prospective population study. Public Health and Environmental Exposure to Cadmium Study Group. Am J Hypertens (2000) 1.26
A meta-analysis of outcome trials in elderly hypertensives. J Hypertens (1992) 1.26
Multiple standardized clinic blood pressures may predict left ventricular mass as well as ambulatory monitoring. A metaanalysis of comparative studies. Am J Hypertens (1995) 1.23
Influence of age on the hemodynamic response to exercise. Circulation (1967) 1.22
Urinary cadmium and lead concentrations and their relation to blood pressure in a population with low exposure. Br J Ind Med (1984) 1.20
Prognostic significance of peak exercise capacity in patients with coronary artery disease. J Am Coll Cardiol (1994) 1.20
Birth weight and body composition in young adult men--a prospective twin study. Int J Obes Relat Metab Disord (2001) 1.19
Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol (2005) 1.18
Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension (1988) 1.17
The relationship between body weight and blood pressure. J Hum Hypertens (1988) 1.15
Four urinary cations and blood pressure. A population study in two Belgian towns. Am J Epidemiol (1983) 1.14
Hypotensive action and side effects of clonidine-chlorthalidone and methyldopa-chlorthalidone in treatment of hypertension. Br Med J (1970) 1.14
The influence of menopause on blood pressure. J Hum Hypertens (1989) 1.13
Blood Pressure Monitoring. Task force III: Target-organ damage, morbidity and mortality. Blood Press Monit (1999) 1.13
Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Cell Death Differ (2007) 1.13
High pp60c-src level in human platelet dense bodies. Blood (1989) 1.11
Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart J (1984) 1.11
INDANA: a meta-analysis on individual patient data in hypertension. Protocol and preliminary results. Therapie (1995) 1.10
Comparative hemodynamic studies in man of adrenergic bepta-1-receptors agents without (h 93/26 equal to metoprolol) or with (h 87/07) intrinsic sympathicomimetic activity. Acta Pharmacol Toxicol (Copenh) (1975) 1.10
Cardiac structure and function in cyclists and runners. Comparative echocardiographic study. Br Heart J (1984) 1.09
Hypertension in the elderly. Hypertension seminars at Ostra Hospital, Göteborg, Sweden. Acta Med Scand (1981) 1.09
Secondary prevention with beta-adrenoceptor blockers in post-myocardial infarction patients. Am Heart J (1982) 1.08
Relationship between phosphorylation and activity of heme-regulated eukaryotic initiation factor 2 alpha kinase. Proc Natl Acad Sci U S A (1981) 1.07
Outcome of recent thromboembolic occlusions of limb arteries treated with streptokinase. Br Med J (1970) 1.07
Health effects of environmental exposure to cadmium: objectives, design and organization of the Cadmibel Study: a cross-sectional morbidity study carried out in Belgium from 1985 to 1989. Environ Health Perspect (1990) 1.07
Salt and blood pressure in Belgium. J Epidemiol Community Health (1981) 1.06
Prognostic value of training-induced change in peak exercise capacity in patients with myocardial infarcts and patients with coronary bypass surgery. Am J Cardiol (1995) 1.06
ESH-ESC guidelines for the management of hypertension. Herz (2006) 1.05
Treatment with beta-blockers for the primary prevention of the cardiovascular complications of hypertension. Eur Heart J (1999) 1.05
Both T cell receptor (TcR)-CD3 complex and CD2 increase the tyrosine kinase activity of p56lck. CD2 can mediate TcR-CD3-independent and CD45-dependent activation of p56lck. Eur J Immunol (1992) 1.04
Public health implications of environmental exposure to cadmium and lead: an overview of epidemiological studies in Belgium. Working Groups. J Cardiovasc Risk (1996) 1.03
The international database of self-recorded blood pressures in normotensive and untreated hypertensive subjects. Blood Press Monit (1999) 1.03
The inheritance of left ventricular structure and function assessed by imaging and Doppler echocardiography. Am Heart J (1991) 1.03